Trial Profile
A Phase Ib, Dose-finding and Pharmacodynamic Study of NVX-508 in Sickle Cell Disease Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NVX 508 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 12 Jul 2018 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 12 Jul 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
- 12 Jul 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.